The intricate web of modern medicine presents a formidable challenge for clinicians, who must navigate countless variables to determine the safest and most effective prescriptions for their patients. In a decisive move to address this complexity, Seegnal Inc. has announced the strategic appointment of Yura Zharkovsky as the new Vice President of Artificial Intelligence for its subsidiary, Seegnal E-Health Ltd., a hire effective January 4, 2026. This appointment signals a major acceleration in the company’s quest to pioneer a new frontier in prescription intelligence, tasking Zharkovsky with spearheading the development of Seegnal Guard, the company’s next-generation system. His work is central to realizing the ambitious vision of a global “Intelligence Layer of Prescriptions.” The primary focus will be on embedding advanced predictive and personalization capabilities into the platform, all while adhering to Seegnal’s foundational belief that technology must serve to augment, not replace, the indispensable expertise of human clinicians in their critical decision-making processes.
A Vision for AI-Augmented Clinical Judgment
Mr. Zharkovsky arrives at Seegnal with a distinguished track record in applied healthcare AI, most notably from his tenure as Head of AI at NeuroKaire. In that role, he was instrumental in creating a sophisticated AI system designed to optimize treatment selection for individuals with major depressive disorder, a complex field requiring nuanced data interpretation. His expertise lies in the critical translation of vast, complex biomedical data sets into high-reliability AI systems that are both practical and effective for real-world clinical deployment. The company emphasized that this background aligns perfectly with its core values. Zharkovsky is recognized for his rigorous engineering standards, a deeply ethical approach to AI development, and a strong commitment to explainability and transparency—factors essential for earning the trust of clinicians. This synergy is central to Seegnal’s philosophy, which posits that the most powerful application of AI in medicine is one that empowers healthcare professionals with enhanced insights, thereby improving their decision-making process without usurping their final authority.
Transforming Prescribing into a Measurable Capability
The appointment of Yura Zharkovsky represented more than just a leadership addition; it crystallized Seegnal’s strategic roadmap for the future of its AI stack. His primary directive involved leading the technical evolution of the company’s core technology to rapidly advance the development of Seegnal Guard, its flagship prescription intelligence system. The project aimed to move beyond simple risk alerts and into a new realm of proactive and personalized therapeutic guidance. This initiative was championed by Seegnal CEO Elad Bibi-Aviv, who identified Zharkovsky as the ideal leader to help realize this vision. The ultimate objective was to fundamentally transform the act of prescribing from a subjective art into a measurable, AI-led, and governable enterprise capability. By focusing on expanding the platform’s predictive analytics and personalization features, the company sought to create a system that could anticipate potential adverse drug events, suggest optimal therapeutic pathways, and provide clinicians with a comprehensive, data-driven view of each patient’s unique pharmacological profile.
